Michael L Gosselin

US Patent:

20020133001, Sep 19, 2002

Filed:

Nov 27, 2001

Appl. No.:

09/996357

Inventors:

Malcolm Gefter - Lincoln MA, US
David Israel - Concord MA, US
John Joyal - Melrose MA, US
Michael Gosselin - Melrose MA, US

Assignee:

Praecis Pharmaceuticals Inc. - Waltham MA

International Classification:

C07H021/04
A61K039/395
C12P021/02
C12N005/06
C07K016/40

US Classification:

536/023530, 530/391100, 424/178100, 435/069100, 435/326000, 435/320100

Abstract:

The present invention provides therapeutic agents suitable for treating an amyloidogenic disorder, as well as pharmaceutical compositions comprising the therapeutic agents and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an amyloidogenic disorder, e.g., Alzheimer's disease, in a subject by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention.

US Patent:

20110305663, Dec 15, 2011

Filed:

May 2, 2011

Appl. No.:

13/098851

Inventors:

Michael L. Gosselin - Boston MA, US
David Fabrizio - Swampscott MA, US
Joanna F. Swain - Concord MA, US
Tracy Mitchell - Billerica MA, US
Ray Camphausen - Wayland MA, US
Sharon T. Cload - Cambridge MA, US
Eric Furfine - Concord MA, US
Paul E. Morin - Pennington NJ, US
Ranjan Mukherjee - Churchville PA, US
Simeon I. Taylor - Skillman NJ, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 38/20
C07K 19/00
A61K 38/17
A61P 3/10
A61P 3/04
A61K 38/18
A61K 38/28
A61K 38/22
A61K 38/26
C07H 21/00
C12N 15/63
C12N 5/10
C12N 1/21
A61P 3/00
A61P 3/06
A61P 9/00
C07K 14/47

US Classification:

424 852, 530324, 530350, 530399, 530351, 514 11, 514 69, 514 48, 514 91, 514 59, 514 88, 514 52, 514 72, 514 117, 514 97, 536 235, 4353201, 435325, 4352523

Abstract:

The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.

US Patent:

58589694, Jan 12, 1999

Filed:

Jun 6, 1995

Appl. No.:

8/470867

Inventors:

Henry C. Marsh - Reading MA
Richard A.G. Smith - Relgate Surrey, GB
John Lifter - Wellesley MA
Anne Mary Freeman - Bucks, GB
Michael L. Gosselin - Chelsea MA

Assignee:

T Cell Sciences, Inc. - Needham MA

International Classification:

A61K 3817

US Classification:

514 8

Abstract:

Provided are therapeutic methods employing preparations of recombinant soluble Complement Receptor type 1 (sCR1) defined with respect to the distribution of sCR1 glycoforms. The methods are suitable for treatment of disease involving inflammation, inappropriate complement activation, and in thrombotic or shock state conditions. Preferred methods employ sCR1 glycoforms that are sialylated, have a pI of. ltoreq. 5. 1, or have a sialic acid:mannose molar ratio of. gtoreq. 25.

US Patent:

54569095, Oct 10, 1995

Filed:

Aug 7, 1992

Appl. No.:

8/927099

Inventors:

Henry C. Marsh - Reading MA
Richard A. G. Smith - Relgate Surrey, GB
John Lifter - Wellesley MA
Anne M. Freeman - Bucks, GB
Michael L. Gosselin - Chelsea MA

Assignee:

T Cell Sciences, Inc. - Needham MA
SmithKline Beecham p.l.c. - Brentwood

International Classification:

A61K 3836
A61K 3849

US Classification:

424 9463

Abstract:

The present invention relates to novel glycoforms and preparations of the soluble complement receptor type 1 (sCR1), and their uses in the therapy of complement mediated diseases and disorders involving inflammation and inappropriate complement activation and in thrombotic or shock state conditions. The invention provides novel glycoforms and methods for producing, detecting, enriching and purifying such glycoforms. The invention further provides methods of specifically producing a glycoform by recombinant or chemical means. Preferred embodiments of the invention include sialylated glycoforms and glycoforms with a pI. ltoreq. 5. 1 determined by chromatofocusing or with a sialic acid to mannose molar ratio of >0. 25. The glycoforms may be formulated alone in therapeutic compositions or in combination with thrombolytic agents.

US Patent:

60571314, May 2, 2000

Filed:

Nov 5, 1998

Appl. No.:

9/186827

Inventors:

Henry C. Marsh - Reading MA
Richard A. G. Smith - Relgate Surrey, GB
John Lifter - Wellesly MA
Anne Mary Freeman - Bucks, GB
Michael L. Gosselin - Revere MA

Assignee:

Avant Immunotherapeutics, Inc. - Needham MA

International Classification:

C12N 1512
C07K 1447
A61K 3817

US Classification:

435 691

Abstract:

Provided are methods of making preparations of recombinant soluble Complement Receptor type 1 (sCR1) defined with respect to the distribution of sCR1 glycoforms and therapeutic methods using them. The preparations are suitable for treatment of allograft or xenograft rejection, diseases involving inflammation or inappropriate complement activation, and thrombotic or shock state conditions. Preferred methods employ sCR1 glycoforms that are sialylated, have a pI of. ltoreq. 5. 1, or have a sialic acid: mannose molar ratio of. gtoreq. 25.

US Patent:

20220204589, Jun 30, 2022

Filed:

Nov 16, 2021

Appl. No.:

17/527238

Inventors:

- Princeton NJ, US
Michael L. Gosselin - Boston MA, US
Dasa Lipovsek - Pepperell MA, US
Rex Parker - Titusville NJ, US
Ray Camphausen - Wayland MA, US
Jonathan H. Davis - Madison WI, US
David Fabrizio - South Hamilton MA, US

International Classification:

C07K 14/78
A61K 47/64

Abstract:

The present invention relates to polypeptides which include tenth fibronectin type III domains (Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.

US Patent:

20210403561, Dec 30, 2021

Filed:

Sep 10, 2021

Appl. No.:

17/472302

Inventors:

- Princeton NJ, US
Michael L. GOSSELIN - Boston MA, US
Aaron P. YAMNIUK - Lawrenceville NJ, US
Derek A. HOLMES - Lawrenceville NJ, US
Guodong CHEN - East Brunswick NJ, US
Priyanka Apurva MADIA - Franklin Park NJ, US
Richard Yu-Cheng HUANG - Bridgewater NJ, US
Stephen Michael CARL - Howell NJ, US

International Classification:

C07K 16/28
A61K 47/68
C12N 15/85
A61P 29/00

Abstract:

Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TRENT-1 signaling, wherein the antibodies do not bind to one or more FcγRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.

US Patent:

20200283505, Sep 10, 2020

Filed:

Jan 21, 2020

Appl. No.:

16/748085

Inventors:

- PRINCETON NJ, US
Tracy S. MITCHELL - Andover MA, US
Michael L. GOSSELIN - Boston MA, US
Dasa LIPOVSEK - Cambridge MA, US
Juhi JUNEJA - Lexington MA, US

International Classification:

C07K 14/78
C07K 14/765
C12N 15/85

Abstract:

Provided herein are polypeptides which include tenth fibronectin type III domains (Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.